OpenURL Connection Search

Select item for more details and to access through your institution.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-la.
Published in:
Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 2, p. 1, doi. 10.1177/2055217318760642
By:
- Havrdová, Eva;
- Arnold, Douglas L.;
- Bar-Or, Amit;
- Comi, Giancarlo;
- Hartung, Hans-Peter;
- Kappos, Ludwig;
- Lublin, Fred;
- Selmaj, Krzysztof;
- Traboulsee, Anthony;
- Belachew, Shibeshih;
- Bennett, Iain;
- Buffels, Regine;
- Garren, Hideki;
- Han, Jian;
- Julian, Laura;
- Napieralski, Julie;
- Hauser, Stephen L.;
- Giovannoni, Gavin
Publication type:
Article
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Published in:
Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 1, p. 1, doi. 10.1177/2055217318760642
By:
- Havrdová, Eva;
- Arnold, Douglas L.;
- Bar-Or, Amit;
- Comi, Giancarlo;
- Hartung, Hans-Peter;
- Kappos, Ludwig;
- Lublin, Fred;
- Selmaj, Krzysztof;
- Traboulsee, Anthony;
- Belachew, Shibeshih;
- Bennett, Iain;
- Buffels, Regine;
- Garren, Hideki;
- Han, Jian;
- Julian, Laura;
- Napieralski, Julie;
- Hauser, Stephen L.;
- Giovannoni, Gavin
Publication type:
Article
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Published in:
Journal of Neurology, 2024, v. 271, n. 7, p. 4348, doi. 10.1007/s00415-024-12326-z
By:
- Hartung, Hans-Peter;
- Berger, Thomas;
- Bermel, Robert A.;
- Brochet, Bruno;
- Carroll, William M.;
- Holmøy, Trygve;
- Karabudak, Rana;
- Killestein, Joep;
- Nos, Carlos;
- Patti, Francesco;
- Perrin Ross, Amy;
- Vanopdenbosch, Ludo;
- Vollmer, Timothy;
- Buffels, Regine;
- Garas, Monika;
- Kadner, Karen;
- Manfrini, Marianna;
- Wang, Qing;
- Freedman, Mark S.
Publication type:
Article
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Published in:
Journal of Neurology, 2019, v. 266, n. 5, p. 1182, doi. 10.1007/s00415-019-09248-6
By:
- Turner, Benjamin;
- Cree, Bruce A. C.;
- Kappos, Ludwig;
- Montalban, Xavier;
- Papeix, Caroline;
- Wolinsky, Jerry S.;
- Buffels, Regine;
- Fiore, Damian;
- Garren, Hideki;
- Han, Jian;
- Hauser, Stephen L.
Publication type:
Article
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial.
Published in:
European Journal of Neurology, 2022, v. 29, n. 3, p. 790, doi. 10.1111/ene.15171
By:
- Vermersch, Patrick;
- Oreja‐Guevara, Celia;
- Siva, Aksel;
- Van Wijmeersch, Bart;
- Wiendl, Heinz;
- Wuerfel, Jens;
- Buffels, Regine;
- Kadner, Karen;
- Kuenzel, Thomas;
- Comi, Giancarlo
Publication type:
Article
Shorter Infusion Time of Ocrelizumab: Primary Results from the ENSEMBLE PLUS Study in Patients with Relapsing-Remitting Multiple Sclerosis.
Published in:
International Journal of MS Care, 2020, v. 22, n. S2, p. 84
By:
- Perrin Ross, Amy;
- Berger, Thomas;
- Bermel, Robert;
- Freedman, Mark S.;
- Holmøy, Trygve;
- Killestein, Joep;
- Buffels, Regine;
- Garas, Monika;
- Kadner, Karen;
- Manfrini, Marianna;
- McNamara, John;
- Hartung, Hans-Peter
Publication type:
Article
Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
Published in:
British Journal of Haematology, 2003, v. 122, n. 1, p. 161, doi. 10.1046/j.1365-2141.2003.04395_3.x
By:
- Fassas, Athanasios;
- Buffels, Regine;
- Kaloyannidis, Panayotis;
- Anagnostopoulos, Achilles
Publication type:
Article

Found: 7

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-la.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial.

Shorter Infusion Time of Ocrelizumab: Primary Results from the ENSEMBLE PLUS Study in Patients with Relapsing-Remitting Multiple Sclerosis.

Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.